首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | AMH |
| Uniprot No | P27106 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 450-552aa |
| 氨基酸序列 | DKGQDGPCALRELSVDLRAERSVLIPETYQANNCQGACRWPQSDRNPRYG NHVVLLLKMQARGAALGRLPCCVPTAYAGKLLISLSEERISADHVPNMVA TEC |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于AMH重组蛋白的经典研究文献概括：
1. **"Production of recombinant human anti-Müllerian hormone"**
- 作者：Josso N, et al.
- 摘要：首次报道了通过哺乳动物细胞表达系统成功制备重组人AMH，并验证其生物活性可抑制缪勒氏管发育，为后续临床应用奠定基础。
2. **"Recombinant AMH rescues ovarian function in a mouse model"**
- 作者：Durlinger AL, et al.
- 摘要：在小鼠模型中证实重组AMH蛋白通过抑制卵泡发育关键通路(如BMP信号)，调控原始卵泡激活过程，可能用于卵巢储备保护。
3. **"Structural basis of AMH signaling"**
- 作者：Cate RL, et al.
- 摘要：解析了重组AMH蛋白与其受体复合物的晶体结构，揭示其特异性结合AMHR2的分子机制，为靶向药物设计提供结构依据。
(注：以上为模拟文献摘要，实际文献需通过PubMed等学术平台检索近年研究)
**Background of Recombinant AMH Protein**
Anti-Müllerian Hormone (AMH), also known as Müllerian-inhibiting substance (MIS), is a glycoprotein hormone belonging to the transforming growth factor-beta (TGF-β) superfamily. It plays a critical role in sexual differentiation during embryonic development and regulates folliculogenesis in females postnatally. In males, AMH is secreted by Sertoli cells in the fetal testes, triggering the regression of the Müllerian ducts, which otherwise develop into female reproductive structures. In females, AMH is produced by granulosa cells of developing ovarian follicles, serving as a key biomarker for ovarian reserve and follicular recruitment.
Recombinant AMH protein is engineered using biotechnological methods, typically expressed in mammalian cell systems (e.g., CHO or HEK293 cells) or bacterial systems (e.g., *E. coli*). These systems enable large-scale production of bioactive AMH with consistent purity and stability, overcoming limitations of natural extraction, such as low yield and variability. The recombinant form retains the functional homodimeric structure, essential for binding to the AMH type II receptor (AMHR2) and initiating downstream signaling pathways.
Clinically, recombinant AMH is utilized in reproductive medicine to assess ovarian function, predict responses to fertility treatments, and diagnose conditions like polycystic ovary syndrome (PCOS). It also holds therapeutic potential in oncofertility to protect ovarian tissue during chemotherapy and in regenerative medicine for inducing follicular development. Research applications include studying mechanisms of sexual differentiation, folliculogenesis, and AMH-related pathologies.
Recent advances in protein engineering and glycosylation optimization have enhanced its bioactivity and half-life, expanding its utility in both diagnostics and therapeutics. As a non-invasive biomarker and a modulator of reproductive processes, recombinant AMH continues to bridge translational gaps between basic research and clinical innovation.
×
